Cognition Therapeutics, Inc.
CGTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $61 | $0 | $0 | $0 |
| Gross Profit | -$61 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,773 | $11,481 | $10,786 | $8,154 |
| G&A Expenses | $0 | $2,497 | $2,989 | $2,569 |
| SG&A Expenses | $2,541 | $2,497 | $2,989 | $2,569 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6,314 | $13,978 | $13,775 | $10,723 |
| Operating Income | -$6,375 | -$13,978 | -$13,775 | -$10,723 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,445 | $7,244 | $5,295 | $2,881 |
| Pre-Tax Income | -$4,930 | -$6,734 | -$8,480 | -$7,842 |
| Tax Expense | – | $0 | $0 | $0 |
| Net Income | -$4,930 | -$6,734 | -$8,480 | -$7,842 |
| % Margin | – | – | – | – |
| EPS | -0.06 | -0.11 | -0.14 | -0.17 |
| % Growth | 45.5% | 21.4% | 17.6% | – |
| EPS Diluted | -0.06 | -0.11 | -0.14 | -0.17 |
| Weighted Avg Shares Out | 77,952 | 63,691 | 61,828 | 46,431 |
| Weighted Avg Shares Out Dil | 77,952 | 63,691 | 61,828 | 46,431 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $3 | $5 | $5 |
| Depreciation & Amortization | $61 | $61 | $45 | $71 |
| EBITDA | -$4,869 | -$6,670 | -$8,430 | -$7,766 |
| % Margin | – | – | – | – |